Atossa Genetics’ Portfolio Can Detect Breast Cancer. But Can These Products Eradicate It?

Atossa Genetics believes it can prevent breast cancer by 2020 — and in the meantime, capture a unique market opportunity — with their novel cellular and molecular diagnostic risk assessment products for early detection. Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?

Read more »

PDUFA: Kadcyla, Immunogen – Metastasized Breast Cancer

Metastasized breast cancer now has a new therapy on the market, though it remains to be seen whether noticeably dangerous side effects may prevent widespread use. Trastuzumab emtansine (T-DM1) or Kadcyla, produced by Immunogen [Nasdaq: IMGN], is a treatment that targets the HER2 protein.

Read more »

Smart Stocks Watch: Atossa Genetics — FDA-Approved Diagnostic Test for Breast Cancer

Atossa Genetics [Nasdaq: ATOS] is a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer through the detection of precursors to breast cancer.

Read more »

DARA Biosciences Execs Discuss Oncology Supportive Care, In-License Portfolio, and Drug Pipeline

DARA Biosciences has created some buzz as of late, landing on several ‘watch lists’ after the company’s exclusive licensing of three market-ready products for distribution in the United States. CEO/Chief Medical Officer Dr. David Drutz and COO Chris Clement conducted a two-part interview with OneMedRadio discussing developmental milestones and key catalysts for Q4-2012 and 2013.

Read more »

Biocept, Inc. Making Advances in Circulating Tumor Cell Research for Cancers

To date, most CTC capture and detection technologies have not been able to recognize the cytokeratin negative (CK‐) CTCs. Biocept’s Cell Enrichment and Extraction (CEETM) platform allows for the capture of these CK- cells as well as CK+ CTC phenotypes

Read more »

Adherex Enrolls First Patient in Clinical Trial For Metastatic Breast Cancer

In 2010, NCI estimated that 207,090 women were diagnosed with breast cancer, while 39,840 women likely died from the disease.

Read more »

Neo Matrix Can Detect Breast Cancer Years Before Tumor Build-Up

Neo Matrix is a medical devices company that has developed a novel diagnostic test to determine breast cancer risk. The […]

Read more »

Seno Medical Uses Laser-Based Technology For Early cancer Diagnosis

Seno Medical is a company focused on cancer using its new patented opto-acoustic technology.  This new imaging modality combines the […]

Read more »

Blood Tests Can Enable Early Cancer Diagnosis

Scientists have yet to find the magic cure for cancer, but they may have found a way to beat it at its own game.

Read more »

Molecular Diagnostics a Natural Fit for Breast Cancer

The growing global incidence of breast cancer has led to an increased demand for molecular diagnostics tests that aid in diagnosing breast cancer.

Read more »